These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 37514999)

  • 1. Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees.
    Masson LC; Servian CDP; Jardim VH; Dos Anjos D; Dorta ML; Batalha-Carvalho JV; Moro AM; Romão PRT; Souza M; Fiaccadori FS; Fonseca SG
    Vaccines (Basel); 2023 Jun; 11(7):. PubMed ID: 37514999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
    Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
    Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.
    Fadlyana E; Setiabudi D; Kartasasmita CB; Putri ND; Rezeki Hadinegoro S; Mulholland K;
    Lancet Infect Dis; 2023 May; 23(5):545-555. PubMed ID: 36640798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.
    Vargas L; Valdivieso N; Tempio F; Simon V; Sauma D; Valenzuela L; Beltrán C; Castillo-Delgado L; Contreras-Benavides X; Acevedo ML; Acevedo J; Gonzalez RI; Valiente-Echeverría F; Soto-Rifo R; Rosemblatt M; Lopez M; Osorio F; Bono MR
    BMC Med; 2022 Jun; 20(1):216. PubMed ID: 35676738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
    Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster.
    Lau CS; Thundyil J; Oh MLH; Phua SK; Liang YL; Li Y; Huo J; Huang Y; Zhang B; Xu S; Aw TC
    Antibodies (Basel); 2022 Nov; 11(4):. PubMed ID: 36412836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility to SARS-CoV-2 omicron following ChAdOx1 nCoV-19 and BNT162b2 versus CoronaVac vaccination.
    Chua JX; Durrant LG; Chok YL; Lai OM
    iScience; 2022 Nov; 25(11):105379. PubMed ID: 36277260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines.
    Atıcı S; Soysal A; Gönüllü E; Aydemir G; Öner N; Alan S; Engin H; Yıldız M; Karaböcüoğlu M
    Rev Soc Bras Med Trop; 2023; 56():e00462023. PubMed ID: 37493731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2.
    Rammauro F; Carrión F; Olivero-Deibe N; Fló M; Ferreira A; Pritsch O; Bianchi S
    Vaccine; 2022 Aug; 40(35):5189-5196. PubMed ID: 35907676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of adaptive immune responses in healthcare workers who received a Coronavirus disease 2019 vaccine booster dose.
    Klinmalai C; Srisala S; Sahakijpicharn T; Apiwattanakul N
    Health Sci Rep; 2024 Jul; 7(7):e2250. PubMed ID: 39015422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equal Maintenance of Anti-SARS-CoV-2 Antibody Levels Induced by Heterologous and Homologous Regimens of the BNT162b2, ChAdOx1, CoronaVac and Ad26.COV2.S Vaccines: A Longitudinal Study Up to the 4th Dose of Booster.
    do Nascimento TA; Nogami PY; de Oliveira CF; Neto WFF; da Silva CP; Ribeiro ACS; de Sousa AW; Freitas MNO; Chiang JO; Silva FA; das Chagas LL; Carvalho VL; Azevedo RSS; Vasconcelos PFC; Costa IB; Costa IB; Barbagelata LS; das Chagas Junior WD; da Penha Junior ET; Soares LS; Viana GMR; Amarilla AA; Modhiran N; Watterson D; Casseb LMN; Martins LC; Henriques DF
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy.
    Cosan F; Demirel OU; Yalcin D; Sonkaya MM; Uluisik IE; Cecen O; Furuncuoglu Y; Celikmen DM; Kara O; Ceylan E; Avsar T
    BMC Rheumatol; 2023 Jul; 7(1):20. PubMed ID: 37468956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity after a Third COVID-19 mRNA Booster in Solid Cancer Patients Who Previously Received the Primary Heterologous CoronaVac/ChAdOx1 Vaccine.
    Luangdilok S; Wanchaijiraboon P; Pakvisal N; Susiriwatananont T; Zungsontiporn N; Sriuranpong V; Sainamthip P; Suntronwong N; Vichaiwattana P; Wanlapakorn N; Poovorawan Y; Teeyapun N; Tanasanvimon S
    Vaccines (Basel); 2022 Sep; 10(10):. PubMed ID: 36298478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil.
    Paula NM; Conzentino MS; Gonçalves ACA; da Silva R; Weissheimer KV; Kluge CHS; Marins PHSA; Camargo HSC; Farias LRP; Sant'Ana TP; Vargas LR; Aldrighi JD; Lima ÊS; Jacotenski GT; Pedrosa FO; Gonçalves AG; Joucoski E; Huergo LF
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers.
    Benning L; Töllner M; Hidmark A; Schaier M; Nusshag C; Kälble F; Reichel P; Buylaert M; Grenz J; Ponath G; Klein K; Zeier M; Süsal C; Schnitzler P; Morath C; Speer C
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34451982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.